The compound 1-[[(2-methyl-3-furanyl)-oxomethyl]amino]-3-[2-(trifluoromethyl)phenyl]thiourea is a synthetic molecule with a complex structure. It's not a widely known or studied compound, and there isn't much readily available information on its specific properties or applications.
Here's why it's difficult to determine its importance for research without more context:
* **Lack of Published Data:** A quick search on scientific databases doesn't yield any significant results related to this specific compound. This suggests it may be a newly synthesized molecule or one not extensively studied.
* **Limited Information:** The chemical name alone doesn't offer much insight into the compound's potential use. It contains several functional groups (furanyl, oxomethyl, amino, thiourea, trifluoromethyl phenyl), but their specific arrangement and interactions are crucial to its properties.
**To understand the importance of this compound for research, we need additional information:**
* **Purpose of Synthesis:** Why was this compound synthesized? Was it designed for a specific purpose, such as being a drug candidate, a catalyst, or a probe for a particular biological process?
* **Experimental Results:** Are there any studies investigating its activity, properties, or potential applications?
* **Research Area:** What research field is this compound related to? Knowing the area of focus (e.g., medicinal chemistry, materials science, organic chemistry) can provide context.
**General Considerations:**
* **Thiourea Derivatives:** Thiourea derivatives are known to exhibit diverse biological activities, including anti-cancer, anti-inflammatory, and anti-microbial properties. This compound's thiourea moiety could be a key factor in its potential applications.
* **Furanyl Group:** Furanyl groups are found in natural products and have been investigated for their biological activities.
* **Trifluoromethylphenyl Group:** The trifluoromethylphenyl group is a common substituent in pharmaceuticals, often contributing to increased lipophilicity and metabolic stability.
**In Summary:**
Without further context, it's impossible to say with certainty why 1-[[(2-methyl-3-furanyl)-oxomethyl]amino]-3-[2-(trifluoromethyl)phenyl]thiourea is important for research. Its potential importance would depend on the specific research area and the compound's properties and activity.
ID Source | ID |
---|---|
PubMed CID | 970996 |
CHEMBL ID | 1310385 |
CHEBI ID | 105878 |
SCHEMBL ID | 10016496 |
Synonym |
---|
2-[(2-methylfuran-3-yl)carbonyl]-n-[2-(trifluoromethyl)phenyl]hydrazinecarbothioamide |
STK456527 |
smr000199954 |
2-(2-methyl-3-furoyl)-n-[2-(trifluoromethyl)phenyl]hydrazinecarbothioamide |
MLS000581335 , |
CHEBI:105878 |
1-[(2-methylfuran-3-carbonyl)amino]-3-[2-(trifluoromethyl)phenyl]thiourea |
AKOS003312880 |
HMS2512C05 |
CHEMBL1310385 |
SCHEMBL10016496 |
1-[[(2-methyl-3-furanyl)-oxomethyl]amino]-3-[2-(trifluoromethyl)phenyl]thiourea |
Q27183665 |
SR-01000277720-1 |
sr-01000277720 |
xgwrgerynmlwmc-uhfffaoysa-n |
Class | Description |
---|---|
(trifluoromethyl)benzenes | An organofluorine compound that is (trifluoromethyl)benzene and derivatives arising from substitution of one or more of the phenyl hydrogens. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
ATAD5 protein, partial | Homo sapiens (human) | Potency | 16.3601 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
67.9K protein | Vaccinia virus | Potency | 15.8489 | 0.0001 | 8.4406 | 100.0000 | AID720579 |
P53 | Homo sapiens (human) | Potency | 8.4882 | 0.0731 | 9.6858 | 31.6228 | AID504706; AID624305 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 4.4668 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 22.3872 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 2.8184 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 89.1251 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 25.1189 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 2.8184 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 35.4813 | 0.0079 | 8.2332 | 1,122.0200 | AID2546 |
geminin | Homo sapiens (human) | Potency | 19.1464 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 35.4813 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |